DL
Therapeutic Areas
Precigen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PAPZIMEOS (zopapogene imadenovec-drba) | Recurrent Respiratory Papillomatosis (RRP) | Approved |
| AdenoVerse Immunotherapy / Cytokine Therapy | Immuno-oncology, Autoimmune Disorders, Infectious Diseases | Not Specified |
| UltraCAR-T | Hematologic Cancers, Solid Tumors | Not Specified |
Leadership Team at Precigen
HS
Helen Sabzevari, PhD
President and CEO
RR
Rutul R. Shah
Chief Operating Officer
PT
Phil Tennant
Chief Commercial Officer
HT
Harry Thomasian Jr.
Chief Financial Officer
DE
Douglas E. Brough, PhD
SVP, Head of Research
BT
Bryan T. Butman, PhD
SVP, Head of CMC
SM
Steven M. Harasym
Investor Relations
AR
Amy R. Lankford, PhD
SVP, Head of Clinical Operations and Regulatory Affairs
RR
Rob Russell
VP, Head of Human Resources
RJ
Randal J. Kirk
Executive Chairman